Pacific Edge appoints independent director, highlights global market reach

Pacific Edge Limited announced on December 8, 2025, the appointment of Simon Richard Flood as an independent director, as per NZX Listing Rules. Mr. Flood, who joined the board on December 4, 2025, has been determined to be independent, with no relationships or interests that could compromise his impartiality.

The company, headquartered in Dunedin, New Zealand, specializes in bladder cancer diagnostic and prognostic tests under its Cxbladder suite. These non-invasive genomic urine tests are designed for risk stratification of urothelial cancer. Cxbladder boasts an evidence portfolio supported by over 20 years of research and more than 25 peer-reviewed publications, with Cxbladder Triage included in the American Urological Association's Microhematuria Guideline.

Cxbladder is available in the US, Australasia, Israel, and markets across Asia and South America. In the US, over 5,000 urologists have ordered more than 130,000 tests. In New Zealand, Cxbladder is accessible to approximately 70% of the population through public healthcare, with online purchase options also available.